Market research
CUP.F Chugai Pharmaceutical Co., Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 58B
- P/E ratio
- 22.14
- Analyst target
- Not available
- Dividend yield
- 2.0%
- Beta
- 0.55
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- JP3519400000
- Market cap
- 58B
- P/E ratio
- 22.14
- Analyst target
- Not available
- Dividend yield
- 2.0%
- Beta
- 0.55
About
About Chugai Pharmaceutical Co., Ltd
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CUP.F discussion.
5 years, 5 months ago
Chugai Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 22.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.2.
Chugai Pharmaceutical Co., Ltd's total revenue rose by 18.7% to $210B since the same quarter in the previous year.
Its net income has increased by 30.2% to $52B since the same quarter in the previous year.
Finally, its free cash flow grew by 38.7% to $62B since the same quarter in the previous year.
Based on the above factors, Chugai Pharmaceutical Co., Ltd gets an overall score of 5/5.